首页> 外文OA文献 >AB0756 Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis

【2h】

AB0756 Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis

机译：AB0756 Adalimalab在钉子牛皮癣中的初级疗效和安全性来自第3期，随机，安慰剂对照试验与患者患者和没有银屑病关节炎的患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
BE Elewski; PA Rich; F Behrens; G Guillet; Z Geng; O Reyes Servin;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Adalimumab for nail psoriasis: Efficacy and safety from the first 26?weeks of a phase 3, randomized, placebo-controlled trial [J] . Boni E. Elewski, Martin M. Okun, Kim Papp, Journal of the American Academy of Dermatology . 2018,第1期

机译：甲牛皮癣的Adalimumab：来自前26个的疗效和安全性，第3期的时间，随机，安慰剂对照试验
2. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. [J] . Kimball AB, Bensimon AG, Guerin A, American journal of clinical dermatology . 2011,第1期

机译：中度至重度银屑病合并症患者中阿达木单抗的疗效和安全性：亚组分析，来自一项随机，双盲，安慰剂对照，III期临床试验的结果。
3. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial [J] . Mease Philip J., Smolen Josef S., Behrens Frank, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2020,第1期

机译：对生物 - 天真患者的Ixekizumab和Adalimalab的疗效和安全性的头脑比较，有活跃的银屑病关节炎：24周的随机，开放标签，盲评论者试验
4. Extended report: Ixekizumab an interleukin-17A specific monoclonal antibody for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised double-blind placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 [O] . Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, -1

机译：扩展报告：Ixekizumab一种白介素17A特异性单克隆抗体用于治疗初生性活动性银屑病关节炎患者：24周随机双盲安慰剂对照和活性（阿达木单抗）对照期的结果SPIRIT-P1 III期试验
5. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial [O] . Boni E. Elewski, Martin M. Okun, Kim Papp, 2018

机译：用于钉牛皮癣的Adalimumab：从第3期的前26周，随机，安慰剂对照试验的疗效和安全性

AB0756 Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis

著录项

引文网络

相似文献

相关主题

期刊订阅